DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Attard G, Reid AHM, Yap TA. et al
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
J Clin Oncol 2008;
26 (28) 4563-4571
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.